Engineered human Tmpk fused with truncated cell-surface markers: Versatile cell-fate control safety cassettes

Gene Therapy

Volumn 20, Issue 1, 2013, Pages 24-34

  Scaife, M ^a   Pacienza, N ^b   Au, B C Y ^b   Wang, J C M ^a,b   Devine, S ^a   Scheid, E ^c   Lee, C J ^b   Lopez Perez, O ^b   Neschadim, A ^a   Fowler, D H ^d   Foley, R ^c   Medin, J A ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

AZT; cell fate control; lentivirus; TMPK

Indexed keywords

CD34 ANTIGEN; COMPLEMENTARY DNA; HYBRID PROTEIN; LENTIVIRUS VECTOR; TMPK CD19 FUSION PROTEIN; TMPK NERVE GROWTH FACTOR RECEPTOR FUSION PROTEIN; UNCLASSIFIED DRUG; ZIDOVUDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CELL FATE CONTROL GENE THERAPY; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVITY; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE COUNT; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIRAL GENE THERAPY;

ANIMALS; ANTIGENS, CD19; CELL DEATH; CELL LINE, TUMOR; FABRY DISEASE; GENETIC VECTORS; HEK293 CELLS; HUMANS; LENTIVIRUS; LEUKEMIA-LYMPHOMA, ADULT T-CELL; MICE; MICE, INBRED NOD; MICE, SCID; NUCLEOSIDE-PHOSPHATE KINASE; PROTEIN ENGINEERING; RECEPTOR, NERVE GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; TRANSFORMATION, GENETIC; ZIDOVUDINE;

LENTIVIRUS; MURINAE; MUS;

EID: 84871978590     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2011.210     Document Type: Article

References (36)

1. Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 2010; 18: 843-851
2. Brentjens R, Yeh R, Bernal Y, Riviere I, Sadelain M. Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial. Mol Ther 2010; 18: 666-668
3. Bonini C, Ferrari G, Verzeletti S, Servida P, Zappone E, Ruggieri L et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 1997; 276: 1719-1724 (Pubitemid 27421983)
4. Tiberghien P, Ferrand C, Lioure B, Milpied N, Angonin R, Deconinck E et al. Administration of herpes simplex-thymidine kinase-expressing donor T cells with a T-cell-depleted allogeneic marrow graft. Blood 2001; 97: 63-72 (Pubitemid 32061243)
5. Berger C, Flowers ME, Warren EH, Riddell SR. Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSVTK-modified donor T cells after allogeneic hematopoietic cell transplantation. Blood 2006; 107: 2294-2302 (Pubitemid 43345547)
6. Garin MI, Garrett E, Tiberghien P, Apperley JF, Chalmers D, Melo JV et al. Molecular mechanism for ganciclovir resistance in human T lymphocytes transduced with retroviral vectors carrying the herpes simplex virus thymidine kinase gene. Blood 2001; 97: 122-129 (Pubitemid 32061251)
7. Deschamps M, Mercier-Lethondal P, Certoux JM, Henry C, Lioure B, Pagneux C et al. Deletions within the HSV-tk transgene in long-lasting circulating gene-modified T cells infused with a hematopoietic graft. Blood 2007; 110: 3842-3852 (Pubitemid 350248439)
8. Blumenthal M, Skelton D, Pepper KA, Jahn T, Methangkool E, Kohn DB. Effective suicide gene therapy for leukemia in a model of insertional oncogenesis in mice. Mol Ther 2007; 15: 183-192 (Pubitemid 46043664)
9. Willmon CL, Krabbenhoft E, Black ME. A guanylate kinase/HSV-1 thymidine kinase fusion protein enhances prodrug-mediated cell killing. Gene Therapy 2006; 13: 1309-1312 (Pubitemid 44264085)
10. Black ME, Kokoris MS, Sabo P. Herpes simplex virus-1 thymidine kinase mutants created by semi-random sequence mutagenesis improve prodrug-mediated tumor cell killing. Cancer Res 2001; 61: 3022-3026 (Pubitemid 32691949)
11. Ardiani A, Sanchez-Bonilla M, Black ME. Fusion enzymes containing HSV-1 thymidine kinase mutants and guanylate kinase enhance prodrug sensitivity in vitro and in vivo. Cancer Gene Ther 2010; 17: 86-96
12. Akyurek LM, Nallamshetty S, Aoki K, San H, Yang ZY, Nabel GJ et al. Coexpression of guanylate kinase with thymidine kinase enhances prodrug cell killing in vitro and suppresses vascular smooth muscle cell proliferation in vivo. Mol Ther 2001; 3: 779-786 (Pubitemid 32509874)
13. Stasi AD, Tey SK, Fujita Y, Cruz R, Martinez C, Kennedy-Nasser A et al. CASPALLO: phase I clinical trial of allodepleted T cells transduced with inducible caspase 9 suicide gene after haploidentical stem cell transplantation. Mol Ther 2010; 18: S110
14. Tey SK, Dotti G, Rooney CM, Heslop HE, Brenner MK. Inducible caspase 9 suicide gene to improve the safety of allodepleted T cells after haploidentical stem cell transplantation. Biol Blood Marrow Transplant 2007; 13: 913-924 (Pubitemid 47055386)
15. Sato T, Neschadim A, Konrad M, Fowler DH, Lavie A, Medin JA. Engineered human tmpk/AZT as a novel enzyme/prodrug axis for suicide gene therapy. Mol Ther 2007; 15: 962-970 (Pubitemid 46621655)
16. Brundiers R, Lavie A, Veit T, Reinstein J, Schlichting I, Ostermann N et al. Modifying human thymidylate kinase to potentiate azidothymidine activation. J Biol Chem 1999; 274: 35289-35292 (Pubitemid 129512811)
17. Ostermann N, Lavie A, Padiyar S, Brundiers R, Veit T, Reinstein J et al. Potentiating AZT activation: structures of wild-type and mutant human thymidylate kinase suggest reasons for the mutants' improved kinetics with the HIV prodrug metabolite AZTMP. J Mol Biol 2000; 304: 43-53
18. Ramsubir S, Yoshimitsu M, Medin JA. Anti-CD25 targeted killing of bicistronically transduced cells: a novel safety mechanism against retroviral genotoxicity. Mol Ther 2007; 15: 1174-1181 (Pubitemid 46813621)
19. Yoshimitsu M, Higuchi K, Ramsubir S, Nonaka T, Rasaiah VI, Siatskas C et al. Efficient correction of Fabry mice and patient cells mediated by lentiviral transduction of hematopoietic stem/progenitor cells. Gene Therapy 2007; 14: 256-265 (Pubitemid 46152629)
20. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, McCormack MP, Wulffraat N, Leboulch P et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003; 302: 415-419 (Pubitemid 37296260)
21. Hacein-Bey-Abina S, Garrigue A, Wang GP, Soulier J, Lim A, Morillon E et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest 2008; 118: 3132-3142
22. GlaxoSmithKline. (2010). Full Prescribing Information Package Insert for Retrovir
23. Stone MJ, Sausville EA, Fay JW, Headlee D, Collins RH, Figg WD et al. A phase I study of bolus versus continuous infusion of the anti-CD19 immunotoxin, IgG-HD37-dgA, in patients with B-cell lymphoma. Blood 1996; 88: 1188-1197 (Pubitemid 26276793)
24. Messmann RA, Vitetta ES, Headlee D, Senderowicz AM, Figg WD, Schindler J et al. A phase I study of combination therapy with immunotoxins IgG-HD37-deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory CD19(+), CD22(+) B cell lymphoma. Clin Cancer Res 2000; 6: 1302-1313 (Pubitemid 30226212)
25. Omar RF, Gourde P, Desormeaux A, Tremblay M, Beauchamp D, Bergeron MG. In vivo toxicity of foscarnet and zidovudine given alone or in combination. Toxicol Appl Pharmacol 1996; 139: 324-332 (Pubitemid 26281609)
26. Tan X, Boudinot FD, Chu CK, Egron D, Perigaud C, Gosselin G et al. Pharmacokinetics of bis(t-butyl-SATE)-AZTMP, a bispivaloylthioethyl prodrug for intracellular delivery of zidovudine monophosphate, in mice. Antivir Chem Chemother 2000; 11: 203-211 (Pubitemid 30427063)
27. Quevedo MA, Brinon MC. In vitro and in vivo pharmacokinetic characterization of two novel prodrugs of zidovudine. Antiviral Res 2009; 83: 103-111
28. Wannachaiyasit S, Chanvorachote P, Nimmannit U. A novel anti-HIV dextrinzidovudine conjugate improving the pharmacokinetics of zidovudine in rats. AAPS PharmSciTech 2008; 9: 840-850
29. Lapalombella R, Zhao X, Triantafillou G, Yu B, Jin Y, Lozanski G et al. A novel Raji-Burkitt's lymphoma model for preclinical and mechanistic evaluation of CD52-targeted immunotherapeutic agents. Clin Cancer Res 2008; 14: 569-578 (Pubitemid 351226127)
30. Bilello JA, Eiseman JL, Standiford HC, Drusano GL. Impact of dosing schedule upon suppression of a retrovirus in a murine model of AIDS encephalopathy. Antimicrob Agents Chemother 1994; 38: 628-631 (Pubitemid 24072262)
31. Kase R, Shimmoto M, Itoh K, Utsumi K, Kotani M, Taya C et al. Immunohistochemical characterization of transgenic mice highly expressing human lysosomal alpha-galactosidase. Biochim Biophys Acta 1998; 1406: 260-266 (Pubitemid 28269308)
32. Zarate YA, Hopkin RJ. Fabry's disease. Lancet 2008; 372: 1427-1435
33. Amarnath S, Mangus CW, Wang JC, Wei F, He A, Kapoor V et al. The PDL1-PD1 Axis Converts Human TH1 Cells into Regulatory T Cells. Sci Transl Med 2011; 3: 111-120
34. Medin JA, Tudor M, Simovitch R, Quirk JM, Jacobson S, Murray GJ et al. Correction in trans for Fabry disease: expression, secretion and uptake of alpha-galactosidase A in patient-derived cells driven by a high-titer recombinant retroviral vector. Proc Natl Acad Sci USA 1996; 93: 7917-7922
35. Walia JS, Neschadim A, Lopez-Perez O, Alayoubi A, Fan X, Carpentier S et al. Autologous transplantation of lentivector/acid ceramidase-transduced hematopoietic cells in non-human primates. Hum Gene Ther 2011; 22: 679-687
36. Qin G, Takenaka T, Telsch K, Kelley L, Howard T, Levade T et al. Preselective gene therapy for Fabry disease. Proc Natl Acad Sci USA 2001; 98: 3428-3433 (Pubitemid 32220862)